Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2010

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Sunitinib

50mg/day for 4 weeks

OTHER

Tumor biopsy

Conducted prior to administration of sunitinib therapy

PROCEDURE

Nephrectomy

Nephrectomy 2-4 weeks after last dose of Sunitinib

OTHER

Biomarkers

"Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.~Biomarker evaluation of tissue prior to 4 week administration of Sunitinib"

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER